The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Phase II dose optimization study of inobrodib with pomalidomide and dexamethasone in R/R myeloma
Nisha Joseph, MD, Winship Cancer Institute, Emory University, Atlanta, GA, discusses the results of a Phase II dose optimization study (NCT04068597) of inobrodib in combination with pomalidomide and dexamethasone in relapsed/refractory (R/R) multiple myeloma (MM), highlighting the encouraging early clinical activity of this combination in a heavily pretreated patient population. Dr Joseph notes that the all-oral regimen was relatively well-tolerated, with manageable adverse events, and that the 20 milligram dose of inobrodib has been selected for the upcoming DoMMino-1 trial (NCT07096778). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
